A. N. Nesmeyanov Institute of Organoelement Compounds of Russian Academy of Sciences, 119991 st. Vavilova, 28, GSP-1, Moscow 119991, Russian Federation.
D. I. Mendeleev University of Chemistry and Technology of Russia, 125047 Miusskaya sqr., 9, Moscow 119991, Russian Federation.
Inorg Chem. 2024 Nov 11;63(45):21652-21669. doi: 10.1021/acs.inorgchem.4c03116. Epub 2024 Oct 30.
With increasing clinical applications and interest in targeted alpha therapy, there is growing interest in developing alternative chelating agents for [Pb]Pb and [Bi]Bi that exhibit rapid radiolabeling kinetics and kinetic inertness. Herein we report the synthesis and detailed investigation of diacetate and dipicolinate 18- and 21-membered macrocyclic chelators BADA-18, BADA-21, BADPA-18, and BADPA-21 for the complexation of Pb and Bi ions with potential use in the preparation of radiopharmaceuticals. The formation of mononuclear complexes was established by using ESI-mass spectrometry, and their stability constants were determined by potentiometric titration. A thorough study of the structure of the metal complexes was carried out by using X-ray diffraction and NMR spectroscopy. It was shown how the stability of the complex is influenced by an increase in the size of the macrocycle, the replacement of acetate arms with picolinate ones, the rigidity of the ligand, as well as the type of conformation (- or -) of the metal complex. The new ligands were radiolabeled with [Pb]Pb and [Bi]Bi, and the in vitro stability of the resulting complexes in a competitive environment of serum and biologically significant metal ions was assessed. Rapid complex formation in 1-2 min at room temperature, as well as the high kinetic inertness of the complexes Pb(BADPA-18) and Bi(BADPA-18) in biological media, demonstrate its potential for use in targeted radionuclide therapy.
随着靶向 alpha 治疗的临床应用和兴趣的增加,人们对开发替代的 [Pb]Pb 和 [Bi]Bi 螯合剂越来越感兴趣,这些螯合剂具有快速放射性标记动力学和动力学惰性。在此,我们报告了二乙酸酯和二吡啶酸酯 18 元和 21 元大环螯合剂 BADA-18、BADA-21、BADPA-18 和 BADPA-21 的合成及详细研究,用于 Pb 和 Bi 离子的络合,有可能用于制备放射性药物。通过使用 ESI-质谱法确定了单核配合物的形成,通过电位滴定法确定了它们的稳定常数。通过 X 射线衍射和 NMR 光谱对金属配合物的结构进行了深入研究。结果表明,配合物的稳定性如何受到大环尺寸增加、用吡啶酸酯取代乙酸酯臂、配体的刚性以及金属配合物的构象(-或-)类型的影响。用 [Pb]Pb 和 [Bi]Bi 标记了新的配体,并在血清和生物相关金属离子的竞争环境中评估了所得配合物的体外稳定性。在室温下 1-2 分钟内快速形成配合物,以及配合物 Pb(BADPA-18)和 Bi(BADPA-18)在生物介质中的高动力学惰性,表明其在靶向放射性核素治疗中的应用潜力。